Alar Pharmaceuticals Inc. (6785.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan
Alar Pharmaceuticals Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 5.82 m TWD | 2.75 m TWD |
| Gross profit | 3.79 m TWD | 2.14 m TWD |
| Operating income | -67.94 m TWD | -167.80 m TWD |
| EBIT | 37.08 m TWD | -78.89 m TWD |
| Net income | 18.17 m TWD | -79.68 m TWD |
| Diluted EPS – continuing operations | 0.27 TWD | -1.19 TWD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
More stocks
- GoldQuest Mining Corp. (GQC.V)
- Golconda Gold Ltd. (GG.V)
- SAMYANG NC Chem (482630.KQ)
- PEDEVCO CORP (PED)
- Hye Technology Co.,Ltd (6877.TWO)
- Budapesti Ãrtéktozsde Nyilvánosan Muködo Részvénytársaság (BET.BD)
- Taiwan Kong King Co Ltd (3093.TWO)
- TacBright Optronics Corporation (6434.TWO)
- Northeast Group Berhad (0325.KL)
- MakinaRocks (477850.KQ)
- Citra Borneo Utama (CBUT.JK)
- Solar Foods Oyj (SFOODS.HE)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.